A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.

Jian YinMingming ZhaoXianhao XuMeini ZhangZucai XuZunbo LiXinyue QinZhuyi LiChong-Bo ZhaoHongyu ZhouYing MaWenfeng CaoGuoping WangYongzhong LinJizhong ZhangXu ZhangHongbin CaiWeidong QianYiqi WangXinghu ZhangGuangzhi LiuJiawei WangWei QiuLianqiu MinJing LiHui DengLan ChuYifan ZhangJianmin Fang

Published in: European journal of neurology (2024)

Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase 3 clinical trial.

Keyphrases

open label
double blind
clinical trial
phase ii
phase iii
myasthenia gravis
placebo controlled
phase ii study
study protocol
randomized controlled trial
squamous cell carcinoma
locally advanced